US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US6740506B2
(en)
|
1995-12-07 |
2004-05-25 |
Diversa Corporation |
End selection in directed evolution
|
US5830696A
(en)
|
1996-12-05 |
1998-11-03 |
Diversa Corporation |
Directed evolution of thermophilic enzymes
|
US6939689B2
(en)
|
1995-12-07 |
2005-09-06 |
Diversa Corporation |
Exonuclease-mediated nucleic acid reassembly in directed evolution
|
US6361974B1
(en)
|
1995-12-07 |
2002-03-26 |
Diversa Corporation |
Exonuclease-mediated nucleic acid reassembly in directed evolution
|
US6358709B1
(en)
|
1995-12-07 |
2002-03-19 |
Diversa Corporation |
End selection in directed evolution
|
US6238884B1
(en)
|
1995-12-07 |
2001-05-29 |
Diversa Corporation |
End selection in directed evolution
|
US6171820B1
(en)
|
1995-12-07 |
2001-01-09 |
Diversa Corporation |
Saturation mutagenesis in directed evolution
|
US6562594B1
(en)
|
1999-09-29 |
2003-05-13 |
Diversa Corporation |
Saturation mutagenesis in directed evolution
|
US7018793B1
(en)
|
1995-12-07 |
2006-03-28 |
Diversa Corporation |
Combinatorial screening of mixed populations of organisms
|
US6352842B1
(en)
|
1995-12-07 |
2002-03-05 |
Diversa Corporation |
Exonucease-mediated gene assembly in directed evolution
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
US20070059302A1
(en)
*
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
AU743758B2
(en)
*
|
1997-04-07 |
2002-02-07 |
Genentech Inc. |
Anti-VEGF antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
US6887674B1
(en)
|
1998-04-13 |
2005-05-03 |
California Institute Of Technology |
Artery- and vein-specific proteins and uses therefor
|
US6864227B1
(en)
|
1998-04-13 |
2005-03-08 |
California Institute Of Technology |
Artery-and vein-specific proteins and uses therefor
|
AU1728800A
(en)
|
1998-11-18 |
2000-06-05 |
Genentech Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
WO2000034337A1
(en)
*
|
1998-12-10 |
2000-06-15 |
Tsukuba Research Laboratory, Toagosei Co., Ltd. |
Humanized monoclonal antibodies against vascular endothelial cell growth factor
|
DK1140173T4
(da)
*
|
1998-12-22 |
2013-06-10 |
Genentech Inc |
Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
MXPA01010891A
(es)
|
1999-04-28 |
2002-11-07 |
Univ Texas |
Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
|
EP1203026A4
(en)
*
|
1999-07-29 |
2005-03-16 |
Dyax Corp |
FRACTIONS BINDING FIBRIN
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
EP1757311B1
(en)
|
1999-12-24 |
2009-02-11 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
ATE422369T1
(de)
|
1999-12-24 |
2009-02-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
|
CA2709771A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US6902718B2
(en)
|
2000-10-24 |
2005-06-07 |
Diatide, Inc. |
Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
|
US6989138B2
(en)
|
2000-10-24 |
2006-01-24 |
Diatide, Inc. |
Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
US7117096B2
(en)
|
2001-04-17 |
2006-10-03 |
Abmaxis, Inc. |
Structure-based selection and affinity maturation of antibody library
|
TWI284539B
(en)
|
2001-07-30 |
2007-08-01 |
Epix Pharm Inc |
A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
DE60232265D1
(de)
*
|
2001-10-25 |
2009-06-18 |
Genentech Inc |
Glycoprotein-zusammensetzungen
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
DE60325334D1
(de)
|
2002-02-05 |
2009-01-29 |
Genentech Inc |
Proteinaufreinigung
|
CA2478925C
(en)
|
2002-04-26 |
2016-06-07 |
Robert Lee Fahrner |
Non-affinity purification of proteins
|
PL210412B1
(pl)
*
|
2002-05-24 |
2012-01-31 |
Schering Corp |
Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
SI2269656T1
(sl)
|
2002-07-15 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
|
CA2965865C
(en)
|
2002-07-18 |
2021-10-19 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
US7575893B2
(en)
|
2003-01-23 |
2009-08-18 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
ES2531125T3
(es)
|
2003-02-03 |
2015-03-10 |
Ibio Inc |
Sistema para la expresión de genes en plantas
|
US7381410B2
(en)
|
2003-03-12 |
2008-06-03 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
WO2004080425A2
(en)
|
2003-03-12 |
2004-09-23 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
WO2008109433A2
(en)
|
2007-03-02 |
2008-09-12 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
AU2004272972A1
(en)
|
2003-05-22 |
2005-03-24 |
Fraunhofer Usa, Inc. |
Recombinant carrier molecule for expression, delivery and purification of target polypeptides
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
WO2005000900A1
(en)
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Treatment with anti-vegf antibodies
|
PL1648940T3
(pl)
|
2003-07-28 |
2016-12-30 |
|
Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A
|
WO2005012531A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody cdr polypeptide sequences with restricted diversity
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US7920906B2
(en)
|
2005-03-10 |
2011-04-05 |
Dexcom, Inc. |
System and methods for processing analyte sensor data for sensor calibration
|
CA2876822C
(en)
|
2003-08-27 |
2015-11-17 |
David Shima |
Combination therapy for the treatment of ocular neovascular disorders
|
FR2859725B1
(fr)
*
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
US9247900B2
(en)
|
2004-07-13 |
2016-02-02 |
Dexcom, Inc. |
Analyte sensor
|
DK1737971T3
(da)
|
2004-01-20 |
2017-11-13 |
Merus Nv |
Blandinger af bindingsproteiner
|
ATE452147T1
(de)
|
2004-02-19 |
2010-01-15 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
DE602005025459D1
(de)
|
2004-03-12 |
2011-02-03 |
Vasgene Therapeutics Inc |
Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
|
EP1730196B1
(en)
|
2004-03-12 |
2010-12-22 |
Vasgene Therapeutics, Inc. |
Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
|
BRPI0511755A
(pt)
|
2004-06-01 |
2008-01-02 |
Domantis Ltd |
composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
|
US7713574B2
(en)
|
2004-07-13 |
2010-05-11 |
Dexcom, Inc. |
Transcutaneous analyte sensor
|
US20070045902A1
(en)
|
2004-07-13 |
2007-03-01 |
Brauker James H |
Analyte sensor
|
CN102641503A
(zh)
*
|
2004-07-20 |
2012-08-22 |
健泰科生物技术公司 |
血管生成素样4蛋白抑制剂,组合,以及其用途
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
RU2442571C2
(ru)
|
2004-07-23 |
2012-02-20 |
Дженентек, Инк. |
Кристаллизация антител или их фрагментов
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
EP1799713B1
(en)
|
2004-09-23 |
2014-11-05 |
VasGene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
DK1802334T3
(da)
|
2004-10-21 |
2012-10-15 |
Genentech Inc |
Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme
|
KR20070100307A
(ko)
|
2004-12-22 |
2007-10-10 |
제넨테크, 인크. |
가용성 다중 막관통 단백질의 생산 방법
|
US8236283B2
(en)
*
|
2005-01-06 |
2012-08-07 |
Ge Healthcare As |
Optical imaging
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
DK3248600T3
(da)
|
2005-02-18 |
2020-07-06 |
Abraxis Bioscience Llc |
Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US20060217311A1
(en)
|
2005-03-25 |
2006-09-28 |
Daniel Dix |
VEGF antagonist formulations
|
CN101222926B
(zh)
*
|
2005-04-15 |
2013-07-17 |
默沙东公司 |
用于治疗或预防癌症的方法和组合物
|
US20080045949A1
(en)
*
|
2005-06-17 |
2008-02-21 |
Hunt Margaret M |
Method of treating degenerative spinal disorders
|
KR101103108B1
(ko)
*
|
2005-06-20 |
2012-01-04 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2006341615A1
(en)
|
2005-08-03 |
2007-10-18 |
Fraunhofer Usa, Inc. |
Compositions and methods for production of immunoglobulins
|
PL3311805T3
(pl)
|
2005-08-31 |
2020-07-27 |
Abraxis Bioscience, Llc |
Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
KR100877824B1
(ko)
|
2005-11-11 |
2009-01-12 |
한국생명공학연구원 |
E2epf ucp-vhl 상호작용 및 그 용도
|
WO2007059195A1
(en)
*
|
2005-11-14 |
2007-05-24 |
University Of Southern California |
Integrin-binding small molecules
|
TW200804425A
(en)
*
|
2005-12-06 |
2008-01-16 |
Domantis Ltd |
Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
|
AU2006326417B2
(en)
†
|
2005-12-16 |
2012-05-24 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
|
JP5164856B2
(ja)
|
2006-01-05 |
2013-03-21 |
ジェネンテック, インコーポレイテッド |
抗ephb4抗体およびその使用方法
|
EP1976884B1
(en)
|
2006-01-20 |
2012-12-19 |
Genentech, Inc. |
Anti-ephrinb2 antibodies and methods using same
|
CN101454347B
(zh)
|
2006-02-13 |
2013-07-24 |
美国弗劳恩霍夫股份有限公司 |
流感抗原、疫苗组合物和相关方法
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
BRPI0709338A2
(pt)
|
2006-03-21 |
2011-07-12 |
Genentech Inc |
anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
|
TW200812615A
(en)
*
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
UA95797C2
(ru)
*
|
2006-03-22 |
2011-09-12 |
Ф. Хоффманн-Ля Рош Аг |
Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста
|
MX2008012279A
(es)
*
|
2006-03-29 |
2008-10-08 |
Genentech Inc |
Diagnostico y tratamientos para tumores.
|
EP2371865B1
(en)
|
2006-04-07 |
2017-07-12 |
Aerpio Therapeutics, Inc. |
Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
|
TW200815467A
(en)
|
2006-06-06 |
2008-04-01 |
Genentech Inc |
Anti-DLL4 antibodies and methods using same
|
RU2008152435A
(ru)
*
|
2006-06-06 |
2010-07-20 |
Дженентек, Инк. (Us) |
Композиции и способы регулирования развития сосудов
|
SI2364691T1
(sl)
|
2006-06-16 |
2013-08-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
EP2068877A4
(en)
|
2006-07-19 |
2011-09-21 |
Cleveland Clinic Foundation |
COMPOUNDS AND METHODS FOR MODULATING ANGIOGENESIS
|
CN100448892C
(zh)
*
|
2006-08-02 |
2009-01-07 |
中国人民解放军军事医学科学院基础医学研究所 |
抗肿瘤血管内皮生长因子受体vegf-r2抗原及其编码基因与应用
|
MX2009001715A
(es)
|
2006-08-21 |
2009-02-25 |
Hoffmann La Roche |
Terapia tumoral con un anticuerpo anti-vegf.
|
ME02371B
(me)
|
2006-09-29 |
2016-06-20 |
Oncomed Pharm Inc |
Sastojci i postupci za dijagnstikovanje i tretman raka
|
EP2069798B1
(en)
|
2006-10-04 |
2014-04-16 |
Genentech, Inc. |
Elisa for vegf
|
JP2010507594A
(ja)
*
|
2006-10-20 |
2010-03-11 |
シェーリング コーポレイション |
完全ヒト抗vegf抗体および使用方法
|
CA2671734A1
(en)
|
2006-12-19 |
2008-06-26 |
Genentech, Inc. |
Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
WO2008079280A1
(en)
|
2006-12-21 |
2008-07-03 |
Millipore Corporation |
Purification of proteins
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
ES2374330T3
(es)
|
2007-01-22 |
2012-02-15 |
Genentech, Inc. |
Precipitación con polielectrolito y purificación de anticuerpos.
|
WO2008091222A1
(en)
*
|
2007-01-26 |
2008-07-31 |
Bioinvent International Ab |
Dll4 signaling inhibitors and uses thereof
|
CL2008000420A1
(es)
|
2007-02-09 |
2008-06-27 |
Genentech Inc |
Anticuerpo anti-robo4; y su uso para modular la angiogenesis.
|
AU2008251608B2
(en)
|
2007-05-08 |
2014-03-27 |
Genentech, Inc. |
Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
|
MX2009012421A
(es)
|
2007-05-17 |
2009-12-01 |
Genentech Inc |
Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2.
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
EP4335863A2
(en)
|
2007-07-09 |
2024-03-13 |
Genentech, Inc. |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
WO2009009759A2
(en)
|
2007-07-11 |
2009-01-15 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
EP2185594B1
(en)
|
2007-08-13 |
2016-04-06 |
VasGene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to ephb4
|
WO2009025846A2
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
SI2840090T1
(en)
*
|
2007-10-30 |
2018-05-31 |
Genentech, Inc. |
Purification of the antibody by cation exchange chromatography
|
JP5611047B2
(ja)
*
|
2007-11-09 |
2014-10-22 |
ジェネンテック, インコーポレイテッド |
アクチビンレセプター様キナーゼ−1アンタゴニスト組成物とその使用方法
|
EP2614837A1
(en)
|
2007-11-09 |
2013-07-17 |
Affitech Research AS |
Anti-VEGF antibody compositions and methods
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
EP3269366B1
(en)
|
2008-03-18 |
2020-01-15 |
Genentech, Inc. |
Combinations of an anti-her2 antibody-drug conjugate and lapatinib, and methods of use
|
JP5425180B2
(ja)
*
|
2008-03-27 |
2014-02-26 |
ザイモジェネティクス, インコーポレイテッド |
PDGFRβおよびVEGF−Aを阻害するための組成物および方法
|
EP2280997A2
(en)
*
|
2008-04-18 |
2011-02-09 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
PE20100092A1
(es)
|
2008-06-03 |
2010-03-12 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
US8999702B2
(en)
|
2008-06-11 |
2015-04-07 |
Emd Millipore Corporation |
Stirred tank bioreactor
|
US8349322B2
(en)
|
2008-06-25 |
2013-01-08 |
ESBATech, an Alcon Biomedical Research Unit, LLC |
Stable and soluble antibodies inhibiting VEGF
|
MX2010014574A
(es)
*
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
US20100029491A1
(en)
*
|
2008-07-11 |
2010-02-04 |
Maike Schmidt |
Methods and compositions for diagnostic use for tumor treatment
|
WO2010010153A1
(en)
|
2008-07-23 |
2010-01-28 |
F. Hoffmann-La Roche Ag |
Identification of subjects being susceptible to anti-angiogenesis therapy
|
MX2011001506A
(es)
|
2008-08-14 |
2011-03-15 |
Genentech Inc |
Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
|
AR073231A1
(es)
*
|
2008-08-29 |
2010-10-20 |
Genentech Inc |
Metodos diagnosticos y tratamientos para los tumores independientes del vegf (factor de crecimiento endotelial vascular)
|
CA2736029A1
(en)
|
2008-09-05 |
2010-03-11 |
Duke University |
Anti-lipid antibodies
|
EP2684570A1
(en)
|
2008-09-10 |
2014-01-15 |
F. Hoffmann-La Roche AG |
Compositions and methods for the prevention of oxidative degradation of proteins
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
AR073829A1
(es)
|
2008-10-14 |
2010-12-01 |
Genentech Inc |
Variantes de inmunoglobulinas y sus usos.
|
DK2358746T3
(da)
|
2008-11-03 |
2020-12-21 |
Molecular Partners Ag |
Bindingsproteiner til inhibering af vegf-a-receptorinteraktionen
|
KR101719376B1
(ko)
|
2008-11-05 |
2017-03-23 |
제넨테크, 인크. |
연령-관련 황반 변성에서 유전자 다형성
|
SI2752189T1
(sl)
|
2008-11-22 |
2017-02-28 |
F. Hoffmann-La Roche Ag |
Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka
|
CN102257122B
(zh)
|
2008-12-16 |
2015-07-29 |
Emd密理博公司 |
搅拌槽反应器及方法
|
SG171764A1
(en)
|
2008-12-16 |
2011-07-28 |
Millipore Corp |
Purification of proteins
|
KR20160021308A
(ko)
|
2008-12-23 |
2016-02-24 |
제넨테크, 인크. |
암 환자에서의 진단 목적용 방법 및 조성물
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
WO2010081838A2
(en)
|
2009-01-14 |
2010-07-22 |
Novartis Ag |
Sterile prefilled container
|
WO2010091234A2
(en)
|
2009-02-06 |
2010-08-12 |
The General Hospital Corporation |
Methods of treating vascular lesions
|
CN102481341B
(zh)
|
2009-02-23 |
2017-05-17 |
希托马克斯医疗有限公司 |
蛋白原及其使用方法
|
EP2400992B1
(en)
|
2009-02-27 |
2015-07-22 |
Genentech, Inc. |
Methods and compositions for protein labelling
|
CA2755121A1
(en)
|
2009-03-13 |
2010-09-16 |
Neil P. Desai |
Combination therapy with thiocolchicine derivatives
|
DK2411411T3
(en)
|
2009-03-25 |
2016-11-07 |
Hoffmann La Roche |
New anti-alpha5beta1 antibodies and uses thereof
|
WO2010112193A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
US20100256340A1
(en)
|
2009-04-07 |
2010-10-07 |
Ulrich Brinkmann |
Trivalent, bispecific antibodies
|
TWI559930B
(en)
*
|
2009-04-16 |
2016-12-01 |
Abbvie Biotherapeutics Inc |
Anti-tnf-α antibodies and their uses
|
MX2011010955A
(es)
*
|
2009-04-20 |
2012-04-02 |
Genentech Inc |
Terapia complementaria contra el cancer.
|
AU2010245011B2
(en)
|
2009-04-27 |
2015-09-03 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
EP2427479B1
(en)
|
2009-05-07 |
2018-11-21 |
The Regents of The University of California |
Antibodies and methods of use thereof
|
CA2665956A1
(en)
*
|
2009-05-07 |
2010-11-07 |
Samir Patel |
Combination treatment for ocular diseases
|
SG175891A1
(en)
|
2009-05-08 |
2011-12-29 |
Genentech Inc |
Humanized anti-egfl7 antibodies and methods using same
|
KR20170080705A
(ko)
|
2009-05-08 |
2017-07-10 |
백시넥스 인코포레이티드 |
항-cd100 항체 및 이의 사용 방법
|
US8933297B2
(en)
|
2009-06-15 |
2015-01-13 |
Icon Genetics Gmbh |
Nicotiana benthamiana plants deficient in xylosyltransferase activity
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
SG10201510152RA
(en)
|
2009-07-13 |
2016-01-28 |
Genentech Inc |
Diagnostic methods and compositions for treatment of cancer
|
AR078060A1
(es)
|
2009-07-14 |
2011-10-12 |
Novartis Ag |
Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
KR20120089253A
(ko)
*
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Bv8? 또는 g?csf?길항제를 이용한 종양 전이의 억제
|
MY186219A
(en)
|
2009-08-11 |
2021-06-30 |
Genentech Inc |
Production of proteins in glutamine-free cell culture media
|
CA2770321A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Biological markers for monitoring patient response to vegf antagonists
|
TWI451875B
(zh)
*
|
2009-08-15 |
2014-09-11 |
建南德克公司 |
用於治療先前治療過之乳癌之抗-血管新生療法
|
CN108409829A
(zh)
|
2009-09-01 |
2018-08-17 |
弗·哈夫曼-拉罗切有限公司 |
通过改进的a蛋白洗脱增强的蛋白质纯化
|
WO2011028642A1
(en)
|
2009-09-04 |
2011-03-10 |
University Of Louisville Research Foundation, Inc. |
Genetic determinants of prostate cancer risk
|
SG179070A1
(en)
|
2009-09-11 |
2012-04-27 |
Genentech Inc |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
NZ598962A
(en)
|
2009-09-16 |
2014-12-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
WO2011033006A1
(en)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
CA2776144C
(en)
|
2009-09-29 |
2020-10-27 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
EP3485908B1
(en)
|
2009-10-16 |
2021-08-18 |
Mereo BioPharma 5, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
CA2859193C
(en)
|
2009-10-21 |
2023-02-07 |
Genentech, Inc. |
Genetic polymorphisms in age-related macular degeneration
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
ES2565208T3
(es)
|
2009-12-11 |
2016-04-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-VEGF-C y métodos de uso de los mismos
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
SG181834A1
(en)
|
2009-12-21 |
2012-07-30 |
Genentech Inc |
Antibody formulation
|
MY161868A
(en)
|
2009-12-23 |
2017-05-15 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
EP2519536A4
(en)
|
2009-12-29 |
2013-06-05 |
Reddys Lab Ltd Dr |
PROTEIN PURIFICATION BY ION EXCHANGE
|
US20120309056A1
(en)
|
2010-02-04 |
2012-12-06 |
Leon Arnaud |
Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
|
TWI457135B
(zh)
*
|
2010-02-23 |
2014-10-21 |
Genentech Inc |
治療鉑敏感性復發性晚期上皮卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、吉西他濱與抗vegf抗體之組合
|
SI2550018T1
(sl)
|
2010-03-22 |
2019-05-31 |
F. Hoffmann-La Roche Ag |
Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
CN105147613A
(zh)
|
2010-03-29 |
2015-12-16 |
阿布拉科斯生物科学有限公司 |
增强药物递送和治疗剂有效性的方法
|
SG10201906075VA
(en)
|
2010-03-29 |
2019-08-27 |
Abraxis Bioscience Llc |
Methods of treating cancer
|
US20130156755A1
(en)
|
2010-04-19 |
2013-06-20 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
SG184541A1
(en)
|
2010-05-17 |
2012-11-29 |
Emd Millipore Corp |
Stimulus responsive polymers for the purification of biomolecules
|
KR20190067277A
(ko)
|
2010-05-28 |
2019-06-14 |
제넨테크, 인크. |
락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
WO2011153010A1
(en)
|
2010-06-04 |
2011-12-08 |
Abraxis Biosciences, Llc |
Methods of treatment of pancreatic cancer
|
AU2011270828B2
(en)
|
2010-06-24 |
2015-09-24 |
Genentech, Inc. |
Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
|
WO2012003437A1
(en)
|
2010-07-02 |
2012-01-05 |
Genentech, Inc. |
Treatment of vascularized pigment epithelial detachment with anti-vegf therapy
|
WO2012006503A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
SG10201505593VA
(en)
|
2010-07-19 |
2015-09-29 |
Hoffmann La Roche |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
JP2013538338A
(ja)
|
2010-07-19 |
2013-10-10 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗癌治療への応答可能性の増大した患者を同定する方法
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
JP2013537539A
(ja)
|
2010-08-13 |
2013-10-03 |
ジェネンテック, インコーポレイテッド |
疾患の治療のためのIL−1β及びIL−18に対する抗体
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
KR101586128B1
(ko)
|
2010-08-24 |
2016-01-15 |
에프. 호프만-라 로슈 아게 |
디술피드 안정화 ― Fv 단편을 포함하는 이중특이적 항체
|
CN103260639A
(zh)
|
2010-08-26 |
2013-08-21 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
AU2011329125B2
(en)
|
2010-11-15 |
2015-07-30 |
Five Prime Therapeutics, Inc. |
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JOP20210044A1
(ar)
*
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
WO2012095514A1
(en)
|
2011-01-14 |
2012-07-19 |
Vivalis |
Recombinant protein production system
|
MX341921B
(es)
|
2011-02-28 |
2016-09-07 |
Hoffmann La Roche |
Proteinas de union a antigeno.
|
KR101572338B1
(ko)
|
2011-02-28 |
2015-11-26 |
에프. 호프만-라 로슈 아게 |
1가 항원 결합 단백질
|
CN110038135B
(zh)
|
2011-03-17 |
2021-03-05 |
伯明翰大学 |
重新定向的免疫治疗
|
JP5926791B2
(ja)
|
2011-03-29 |
2016-05-25 |
ロシュ グリクアート アーゲー |
抗体Fc変種
|
RS56759B1
(sr)
|
2011-04-01 |
2018-04-30 |
Genentech Inc |
Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
US9932386B2
(en)
|
2011-04-20 |
2018-04-03 |
Acceleron Pharma, Inc. |
Endoglin polypeptides and uses thereof
|
JP2014513128A
(ja)
|
2011-05-03 |
2014-05-29 |
ジェネンテック, インコーポレイテッド |
血管破壊剤とその使用
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
US20130004484A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
EP2732269B1
(en)
|
2011-07-12 |
2017-10-18 |
Epitomics, Inc. |
Facs-based method for obtaining an antibody sequence
|
EP2551348B1
(en)
|
2011-07-29 |
2014-09-24 |
Icon Genetics GmbH |
Production of galactosylated N-glycans in plants
|
EP2744825A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Inhibition of angiogenesis in refractory tumors
|
HRP20230078T1
(hr)
|
2011-09-23 |
2023-05-12 |
Mereo Biopharma 5, Inc. |
Sredstva za vezivanje vegf/dll4 i njihova uporaba
|
CA2850571C
(en)
|
2011-10-04 |
2021-01-05 |
Icon Genetics Gmbh |
Nicotiana benthamiana plants deficient in fucosyltransferase activity
|
KR101999872B1
(ko)
|
2011-10-11 |
2019-07-12 |
백시넥스 인코포레이티드 |
혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
|
ES2774972T3
(es)
*
|
2011-10-13 |
2020-07-23 |
Aerpio Therapeutics Inc |
Tratamiento de enfermedades oculares
|
EP3505182A1
(en)
|
2011-10-13 |
2019-07-03 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome and cancer
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
US9988424B2
(en)
|
2011-12-05 |
2018-06-05 |
Duke University |
Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
|
US8790652B2
(en)
|
2011-12-06 |
2014-07-29 |
Vaccinex, Inc. |
Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
CN104125963B
(zh)
|
2011-12-22 |
2018-08-17 |
弗·哈夫曼-拉罗切有限公司 |
使用离子交换膜层析改进下游蛋白质纯化步骤的方法
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
CN104203268A
(zh)
|
2012-01-13 |
2014-12-10 |
霍夫曼-拉罗奇有限公司 |
用于识别适于用vegf拮抗剂治疗的患者的生物标记物
|
CN104105711B
(zh)
|
2012-02-10 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
单链抗体及其他异多聚体
|
WO2013127829A1
(en)
|
2012-02-27 |
2013-09-06 |
Universitat De Barcelona |
Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
|
WO2013135602A2
(en)
|
2012-03-13 |
2013-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of ovarian cancer
|
KR20200037425A
(ko)
|
2012-03-27 |
2020-04-08 |
제넨테크, 인크. |
재조합 단백질을 위한 개선된 수확 작업
|
CN104271157A
(zh)
|
2012-03-30 |
2015-01-07 |
霍夫曼-拉罗奇有限公司 |
用于治疗癌症的诊断方法和组合物
|
SG10201607369QA
(en)
|
2012-04-20 |
2016-10-28 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
WO2013170182A1
(en)
|
2012-05-11 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with an hsp90 inhibitory compound
|
US10494440B2
(en)
|
2012-05-11 |
2019-12-03 |
Vaccinex, Inc. |
Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
|
KR102129636B1
(ko)
|
2012-05-31 |
2020-07-03 |
제넨테크, 인크. |
Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
|
PL3679922T3
(pl)
|
2012-06-01 |
2022-01-03 |
Novartis Ag |
Strzykawka
|
CN104379163A
(zh)
|
2012-06-08 |
2015-02-25 |
霍夫曼-拉罗奇有限公司 |
用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
|
KR20150023889A
(ko)
|
2012-06-27 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
JOP20200175A1
(ar)
|
2012-07-03 |
2017-06-16 |
Novartis Ag |
حقنة
|
AU2013288641B2
(en)
|
2012-07-13 |
2017-07-06 |
Roche Glycart Ag |
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
|
EP2882454B1
(en)
|
2012-08-07 |
2018-10-10 |
F.Hoffmann-La Roche Ag |
Combination therapy for the treatment of glioblastoma
|
KR102123134B1
(ko)
|
2012-09-19 |
2020-06-15 |
제넨테크, 인크. |
단백질로의 노르류신 오혼입을 방지하기 위한 방법 및 조성물
|
US9599620B2
(en)
|
2012-10-31 |
2017-03-21 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a DLL4 antagonist
|
MY171664A
(en)
|
2012-11-01 |
2019-10-22 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
|
WO2014074218A1
(en)
|
2012-11-12 |
2014-05-15 |
Redwood Bioscience, Inc. |
Compounds and methods for producing a conjugate
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
US9605078B2
(en)
|
2012-11-16 |
2017-03-28 |
The Regents Of The University Of California |
Pictet-Spengler ligation for protein chemical modification
|
CN104995303A
(zh)
|
2012-12-18 |
2015-10-21 |
诺华股份有限公司 |
利用结合乙酰透明质酸的肽标签的组合物和方法
|
US9393327B2
(en)
|
2012-12-19 |
2016-07-19 |
Genentech, Inc. |
Methods and compositions for radiohalogen protein labeling
|
CA2930987A1
(en)
|
2013-01-11 |
2014-07-17 |
Massachusetts Eye And Ear Infirmary |
Cyp450 lipid metabolites reduce inflammation and angiogenesis
|
EP2951307B1
(en)
|
2013-02-04 |
2019-12-25 |
Vascular Biogenics Ltd. |
Methods of inducing responsiveness to anti-angiogenic agent
|
RU2699007C2
(ru)
|
2013-02-18 |
2019-09-02 |
Ведженикс Пти Лимитед |
Молекулы, связывающие лиганды, и их применение
|
EP3744345B1
(en)
|
2013-03-13 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
EP2968544A4
(en)
|
2013-03-15 |
2016-10-12 |
Hoffmann La Roche |
CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
PL2992012T3
(pl)
|
2013-04-29 |
2019-12-31 |
F. Hoffmann-La Roche Ag |
Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania
|
MX2015015426A
(es)
|
2013-05-23 |
2016-06-10 |
Five Prime Therapeutics Inc |
Metodos de tratamiento de cancer.
|
KR101541478B1
(ko)
*
|
2013-05-31 |
2015-08-05 |
동아쏘시오홀딩스 주식회사 |
항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
|
WO2014209802A1
(en)
|
2013-06-25 |
2014-12-31 |
Vaccinex, Inc. |
Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
|
CA2915255A1
(en)
|
2013-07-12 |
2015-01-15 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological conditions
|
MX2016001854A
(es)
|
2013-08-12 |
2016-09-06 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento.
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
NZ630881A
(en)
|
2013-10-10 |
2016-03-31 |
Vaccinex Inc |
Use of semaphorin-4d binding molecules for treatment of atherosclerosis
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
NZ630892A
(en)
|
2013-10-21 |
2016-03-31 |
Vaccinex Inc |
Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
|
KR20220013459A
(ko)
|
2013-10-25 |
2022-02-04 |
악셀레론 파마 인코포레이티드 |
섬유화 질환을 치료하기 위한 엔도글린 펩티드
|
EP3071181B1
(en)
|
2013-11-18 |
2021-03-24 |
Formycon AG |
Pharmaceutical composition of an anti-vegf antibody
|
CN105744935B
(zh)
|
2013-11-27 |
2022-09-30 |
雷德伍德生物科技股份有限公司 |
肼基-吡咯并化合物及用于生成缀合物的方法
|
EP3089993A1
(en)
*
|
2013-12-31 |
2016-11-09 |
Development Center for Biotechnology |
Anti-vegf antibodies and use thereof
|
EP3842455A1
(en)
|
2014-01-15 |
2021-06-30 |
F. Hoffmann-La Roche AG |
Fc-region variants with improved protein a-binding
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
MX2016010505A
(es)
|
2014-02-14 |
2017-04-13 |
S Chi Andrew |
Metodos mejorados para el tratamiento de canceres vascularizantes.
|
US20170051062A1
(en)
|
2014-02-18 |
2017-02-23 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
|
WO2015128795A1
(en)
|
2014-02-25 |
2015-09-03 |
Dr. Reddy's Laboratories Limited |
Process for modifying galactosylation and g0f content of a glycoprotein composition by glutamine supplementation
|
PT3116891T
(pt)
|
2014-03-10 |
2020-05-18 |
Richter Gedeon Nyrt |
Purificação de imunoglobulina utilizando passos de pré-limpeza
|
UY36032A
(es)
|
2014-03-14 |
2015-10-30 |
Novartis Ag |
Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
SG11201608106PA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
CR20160561A
(es)
|
2014-05-01 |
2017-05-03 |
Genentech Inc |
Variantes del anticuerpo anti-factor d y sus usos
|
EP3828202A1
(en)
|
2014-05-12 |
2021-06-02 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
MX2016014753A
(es)
|
2014-05-15 |
2017-03-06 |
Bristol Myers Squibb Co |
Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno.
|
KR102557615B1
(ko)
|
2014-06-06 |
2023-07-20 |
레드우드 바이오사이언스 인코포레이티드 |
항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
US20170327553A1
(en)
|
2014-06-25 |
2017-11-16 |
Novartis Ag |
Compositions and methods for long acting proteins
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
NZ765734A
(en)
|
2014-07-09 |
2024-01-26 |
Genentech Inc |
Ph adjustment to improve thaw recovery of cell banks
|
JP2017523776A
(ja)
|
2014-07-14 |
2017-08-24 |
ジェネンテック, インコーポレイテッド |
膠芽腫の診断方法及びその治療用組成物
|
US10166273B2
(en)
|
2014-08-12 |
2019-01-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
|
CN105330739B
(zh)
*
|
2014-08-12 |
2020-12-25 |
中美华世通生物医药科技(武汉)有限公司 |
与人血管内皮生长因子特异性结合的抗体或其抗原结合片段及其用途
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
WO2016040880A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
WO2016044334A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
WO2016061142A1
(en)
|
2014-10-14 |
2016-04-21 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
JP6849590B2
(ja)
|
2014-10-17 |
2021-03-24 |
コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. |
ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
|
WO2016065329A1
(en)
|
2014-10-24 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
CN107530419B
(zh)
|
2014-10-31 |
2021-05-18 |
昂考梅德药品有限公司 |
治疗疾病的组合疗法
|
EP3218403B1
(en)
|
2014-11-10 |
2020-05-13 |
F.Hoffmann-La Roche Ag |
Anti-interleukin-33 antibodies and uses thereof
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
CN112826934A
(zh)
|
2014-12-11 |
2021-05-25 |
拜耳医药保健有限责任公司 |
具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
RU2710735C2
(ru)
|
2014-12-23 |
2020-01-10 |
Дженентек, Инк. |
Композиции и способы лечения и диагностики резистентного к химиотерапии рака
|
MX2017009759A
(es)
|
2015-01-28 |
2017-10-27 |
Pfizer |
Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
|
JP2018507914A
(ja)
|
2015-03-09 |
2018-03-22 |
インテクリン・セラピューティクス・インコーポレイテッド |
非アルコール性脂肪肝疾患および/またはリポジストロフィーの処置のための方法
|
JP7044553B2
(ja)
|
2015-04-24 |
2022-03-30 |
ジェネンテック, インコーポレイテッド |
結合ポリペプチドを含む細菌を特定する方法
|
WO2016191751A1
(en)
|
2015-05-28 |
2016-12-01 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
JP2018518483A
(ja)
|
2015-06-08 |
2018-07-12 |
ジェネンテック, インコーポレイテッド |
抗ox40抗体及びpd−1軸結合アンタゴニストを使用して癌を治療する方法
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
JP2018522887A
(ja)
|
2015-07-14 |
2018-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
免疫チェックポイント阻害剤を使用する癌の処置法
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
EP3328886B1
(en)
|
2015-07-29 |
2020-09-16 |
Allergan, Inc. |
Heavy chain only antibodies to ang-2
|
HU231463B1
(hu)
|
2015-08-04 |
2024-01-28 |
Richter Gedeon Nyrt. |
Módszer rekombináns proteinek galaktóz tartalmának növelésére
|
JP2018523673A
(ja)
|
2015-08-14 |
2018-08-23 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
Pdgfに対する重鎖のみ抗体
|
EP3337508A4
(en)
*
|
2015-08-21 |
2019-04-03 |
Immunomedics, Inc. |
MONOCLONAL ANTI-HLA-DR ANTIBODY FOR SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANT TUMORS
|
CN116440279A
(zh)
|
2015-09-17 |
2023-07-18 |
伊缪诺金公司 |
包含抗folr1免疫缀合物的治疗组合
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
DK3353196T3
(da)
|
2015-09-22 |
2023-02-20 |
Inst Nat Sante Rech Med |
Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
|
US11339213B2
(en)
|
2015-09-23 |
2022-05-24 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
CN116987187A
(zh)
|
2015-09-23 |
2023-11-03 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
JP6835836B2
(ja)
|
2015-10-13 |
2021-02-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
脈絡膜血管新生の処置のための方法及び医薬組成物
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
US10654932B2
(en)
|
2015-10-30 |
2020-05-19 |
Genentech, Inc. |
Anti-factor D antibody variant conjugates and uses thereof
|
CN108602881A
(zh)
|
2015-10-30 |
2018-09-28 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体制剂
|
SG10202001808VA
(en)
|
2015-10-30 |
2020-04-29 |
Genentech Inc |
Anti-htra1 antibodies and methods of use thereof
|
SI3370768T1
(sl)
|
2015-11-03 |
2022-04-29 |
Janssen Biotech, Inc. |
Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
|
EP3370764A4
(en)
|
2015-11-05 |
2019-07-17 |
The Regents of The University of California |
CELLS MARKED BY LIPID CONJUGATES AND METHODS OF USING THE SAME
|
WO2018218013A2
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
WO2017085253A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
MX2018006092A
(es)
|
2015-11-18 |
2019-01-31 |
Formycon Ag |
Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
|
JP7430485B2
(ja)
|
2015-11-18 |
2024-02-13 |
エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド |
眼科用製剤のための薬剤パッケージ
|
KR102183910B1
(ko)
|
2015-12-03 |
2020-11-27 |
리제너론 파마슈티칼스 인코포레이티드 |
항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
SG11201805420SA
(en)
|
2015-12-30 |
2018-07-30 |
Kodiak Sciences Inc |
Antibodies and conjugates thereof
|
CA3011638C
(en)
|
2016-01-26 |
2023-01-10 |
Formycon Ag |
Liquid formulation of a vegf antagonist
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
CA3019373A1
(en)
|
2016-03-29 |
2017-10-05 |
Geltor, Inc. |
Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
PL3443350T3
(pl)
|
2016-04-15 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Sposoby monitorowania i leczenia nowotworu
|
EA201892587A1
(ru)
|
2016-05-20 |
2019-04-30 |
Биохэйвен Фармасьютикал Холдинг Компани Лтд. |
Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака
|
JP7050702B2
(ja)
|
2016-07-08 |
2022-04-08 |
ジェネンテック, インコーポレイテッド |
Nrf2及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法
|
CN109690315A
(zh)
|
2016-07-08 |
2019-04-26 |
豪夫迈·罗氏有限公司 |
人附睾蛋白4(he4)用于评估muc16阳性癌症治疗的响应性的用途
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
BR112019001206A2
(pt)
|
2016-07-20 |
2019-06-25 |
Aerpio Therapeutics Inc |
anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
|
WO2018018613A1
(zh)
|
2016-07-29 |
2018-02-01 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
CN106222129A
(zh)
*
|
2016-07-29 |
2016-12-14 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
WO2018031865A1
(en)
|
2016-08-12 |
2018-02-15 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
|
EP3783022A3
(en)
|
2016-08-23 |
2021-06-30 |
MedImmune Limited |
Anti-vegf-a antibodies and uses thereof
|
US20190300607A1
(en)
|
2016-10-12 |
2019-10-03 |
Daiichi Sankyo Company, Limited |
Composition containing anti-robo4 antibody and other agents
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
EP3565839A4
(en)
|
2017-01-05 |
2021-04-21 |
Gensun Biopharma Inc. |
CHECKPOINT REGULATOR ANTAGONISTS
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
WO2018132516A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
CN110546277B
(zh)
|
2017-03-01 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
CN110582510B
(zh)
*
|
2017-03-24 |
2023-09-15 |
科学与工业研究委员会 |
用于纯化重组抗体片段的方法
|
JP2020515639A
(ja)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
進行性核上性麻痺の処置のためのPPARγアゴニスト
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
JP7282689B2
(ja)
|
2017-05-19 |
2023-05-29 |
カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ |
リフォールディングした組み換えヒト化ラニビズマブの製造方法
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
EP3630043A1
(en)
|
2017-05-24 |
2020-04-08 |
Formycon AG |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
SG11201912473PA
(en)
|
2017-06-22 |
2020-01-30 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
WO2019009265A1
(ja)
|
2017-07-04 |
2019-01-10 |
第一三共株式会社 |
視細胞変性を伴う網膜変性疾患用薬
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
WO2019057946A1
(en)
|
2017-09-25 |
2019-03-28 |
F. Hoffmann-La Roche Ag |
MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
CN111356480A
(zh)
|
2017-10-20 |
2020-06-30 |
脉管生物生长有限公司 |
用于抗血管生成剂疗法的诊断方法
|
EP3727468A4
(en)
|
2017-12-19 |
2021-09-22 |
Akouos, Inc. |
AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR
|
WO2019129679A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
CN110283248B
(zh)
*
|
2018-01-05 |
2020-07-28 |
百奥泰生物制药股份有限公司 |
一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
|
EP3749359A1
(en)
|
2018-02-06 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Treatment of ophthalmologic diseases
|
WO2019173692A2
(en)
|
2018-03-09 |
2019-09-12 |
Agenus Inc. |
Anti-cd73 antibodies and methods of use thereof
|
TW201943428A
(zh)
|
2018-04-16 |
2019-11-16 |
大陸商上海岸闊醫藥科技有限公司 |
預防或治療腫瘤療法副作用的方法
|
KR20210021299A
(ko)
|
2018-05-10 |
2021-02-25 |
리제너론 파아마슈티컬스, 인크. |
고농도 vegf 수용체 융합 단백질 함유 제제
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
WO2019229116A1
(en)
|
2018-05-31 |
2019-12-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
|
CN112638401A
(zh)
|
2018-06-29 |
2021-04-09 |
璟尚生物制药公司 |
抗肿瘤拮抗剂
|
EP4368699A2
(en)
|
2018-07-03 |
2024-05-15 |
Bristol-Myers Squibb Company |
Methods of producing recombinant proteins
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
CN109053895B
(zh)
|
2018-08-30 |
2020-06-09 |
中山康方生物医药有限公司 |
抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
|
CN113164597A
(zh)
|
2018-09-24 |
2021-07-23 |
爱尔皮奥制药公司 |
靶向HPTP-β(VE-PTP)和VEGF的多特异性抗体
|
KR20210074341A
(ko)
|
2018-10-10 |
2021-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
HUP1800376A2
(hu)
|
2018-11-07 |
2020-05-28 |
Richter Gedeon Nyrt |
Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
CN109134651B
(zh)
*
|
2018-12-03 |
2019-02-22 |
上海复宏汉霖生物技术股份有限公司 |
一种抗vegf的单克隆抗体及其制备方法和应用
|
WO2020118043A1
(en)
|
2018-12-07 |
2020-06-11 |
Coherus Biosciences, Inc. |
Methods for producing recombinant proteins
|
CN113226472A
(zh)
|
2018-12-17 |
2021-08-06 |
雷维托普有限公司 |
双免疫细胞衔接物
|
KR20210139329A
(ko)
|
2019-03-13 |
2021-11-22 |
바스큘라 바이오제닉스 리미티드 |
항종양 요법의 방법
|
AR118536A1
(es)
|
2019-04-01 |
2021-10-20 |
Genentech Inc |
Composiciones y métodos para estabilizar formulaciones que contienen proteína
|
HU231498B1
(hu)
|
2019-04-04 |
2024-05-28 |
Richter Gedeon Nyrt |
Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelõzõ flokkulálás alkalmazásával
|
CN113993885A
(zh)
|
2019-04-12 |
2022-01-28 |
格尔托公司 |
重组弹性蛋白及其生产
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
TW202106699A
(zh)
|
2019-04-26 |
2021-02-16 |
美商愛德維仁生物科技公司 |
用於玻璃體內遞送之變異體aav蛋白殼
|
AU2020270376A1
(en)
|
2019-05-03 |
2021-10-07 |
Genentech, Inc. |
Methods of treating cancer with an anti-PD-L1 antibody
|
US20220211847A1
(en)
|
2019-05-06 |
2022-07-07 |
Medimmune Limited |
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
CN114340735A
(zh)
|
2019-06-28 |
2022-04-12 |
璟尚生物制药公司 |
突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
|
EP4007808A1
(en)
|
2019-08-01 |
2022-06-08 |
Bristol-Myers Squibb Company |
Methods of improving protein productivity in fed-batch cell cultures
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021072210A1
(en)
|
2019-10-11 |
2021-04-15 |
Coherus Biosciences, Inc. |
Methods of purifying ranibizumab or a ranibizumab variant
|
WO2021072182A1
(en)
|
2019-10-11 |
2021-04-15 |
Coherus Biosciences, Inc. |
Methods for producing ranibizumab
|
US20230022576A1
(en)
|
2019-11-19 |
2023-01-26 |
Protalix Ltd. |
Removal of constructs from transformed cells
|
MX2022006330A
(es)
|
2019-11-25 |
2022-08-17 |
Akeso Biopharma Inc |
Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
|
US20230151425A1
(en)
|
2020-03-11 |
2023-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
|
CN115605507A
(zh)
|
2020-03-13 |
2023-01-13 |
基因泰克公司(Us) |
抗白介素-33抗体及其用途
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
US20220023405A1
(en)
|
2020-06-30 |
2022-01-27 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
WO2022013787A1
(en)
|
2020-07-16 |
2022-01-20 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
WO2022066595A1
(en)
|
2020-09-22 |
2022-03-31 |
Bristol-Myers Squibb Company |
Methods for producing therapeutic proteins
|
EP4225902A1
(en)
|
2020-10-05 |
2023-08-16 |
Protalix Ltd. |
Dicer-like knock-out plant cells
|
CN116390767A
(zh)
|
2020-10-15 |
2023-07-04 |
基因泰克公司 |
用于长效递送治疗剂的多功能蛋白聚糖 (vg1) 的透明质酸结合衍生物
|
KR20230088781A
(ko)
|
2020-11-13 |
2023-06-20 |
제넨테크, 인크. |
고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물
|
AU2021391433A1
(en)
|
2020-12-01 |
2023-06-22 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
WO2022157715A1
(en)
|
2021-01-22 |
2022-07-28 |
Dcprime B.V. |
Methods of tumor vaccination
|
MX2023008909A
(es)
|
2021-01-28 |
2023-10-23 |
Janssen Biotech Inc |
Proteínas de unión a psma y usos de estas.
|
JP2024510989A
(ja)
|
2021-03-12 |
2024-03-12 |
メンドゥス・ベスローテン・フェンノートシャップ |
ワクチン接種方法及びcd47遮断薬の使用
|
CN115068603A
(zh)
|
2021-03-12 |
2022-09-20 |
中山康方生物医药有限公司 |
含有抗pd-1-抗vegfa双特异性抗体的药物组合及其用途
|
WO2022232503A1
(en)
|
2021-04-30 |
2022-11-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
TW202313096A
(zh)
|
2021-05-28 |
2023-04-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
衣殼變異的重組腺相關病毒及其應用
|
WO2022256820A1
(en)
|
2021-06-03 |
2022-12-08 |
Gensun Biopharma Inc. |
Multispecific antagonists
|
EP4363449A2
(en)
|
2021-07-02 |
2024-05-08 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
IL309120A
(en)
|
2021-07-28 |
2024-02-01 |
Hoffmann La Roche |
Methods and compositions for the treatment of cancer
|
WO2023015234A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Cell culture methods for producing therapeutic proteins
|
AU2022327397A1
(en)
|
2021-08-13 |
2024-03-14 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-vegf a and -vegf c bispecific antibody and use thereof
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
WO2023049687A1
(en)
|
2021-09-21 |
2023-03-30 |
Bristol-Myers Squibb Company |
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
WO2023150142A1
(en)
|
2022-02-02 |
2023-08-10 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
CN117679505A
(zh)
|
2022-09-09 |
2024-03-12 |
中山康方生物医药有限公司 |
药物组合及用途
|